Mike Payne Discusses Omada Health's Prevent Program

Omada Health’s Prevent program has enrolled nearly 55,000 patients since its start in 2012, and has been demonstrating successful, real world applicable results for patients with pre-diabetes, said Mike Payne, MBA, MSci, chief healthcare development officer at Omada Health.

Transcript (slightly modified)

What is the Omada Health Prevent program and what have been the outcomes so far?

The outcomes have kind of exceeded our expectations, amazingly. We have been treating people since about 2012. We’ve put about 55,000 patients so far into the program, so starting to get to a pretty big sample size but we have big ambitions to drive that into the millions given the size of the epidemic. And, there’s a lot of clinical trial work that’s been done in the diabetes prevention program space. So, we have good yardsticks to compare it by.

And so far for us, we’re seeing results in terms of weight loss, biomarkers like hemoglobin A1c, which tracks blood sugar control, that are quite similar to what was seen in a variety of clinical trials. And so the thing that we’re most pleased about is, unlike a lot of other areas of medicine where the results in the clinical trials were far better than what the results look like in the real world, we’re achieving close to clinical trial results on an on-going basis, in the real world with massive quantities of patients. And so for us, that’s really encouraging that we can not only do this in a controlled environment but we may be able to scale this to a level that’s needed, and that’s 28 million seniors and 87 million total adults in the US with pre-diabetes.